AI Analysis | Feedback

Here are a few brief analogies for STAAR Surgical (STAA):

• Medtronic for the eyes
• Intuitive Surgical for vision correction implants

AI Analysis | Feedback

• Visian Implantable Collamer Lens (ICL) Product Family: Implantable lenses designed to treat a range of visual disorders including myopia, hyperopia, astigmatism, and presbyopia.
• Hyperopic ICL: A specific implantable Collamer lens used to correct far-sightedness.
• Preloaded Silicone Cataract Intraocular Lenses: Lenses implanted during cataract surgery to replace the eye's natural clouded lens.
• Companion Delivery and Injector Systems: Instruments and devices used to safely deliver the various implantable lenses into the eye during surgical procedures.

AI Analysis | Feedback

• Ophthalmic surgeons, and vision and surgical centers.
• Hospitals and government facilities.
• Distributors.

AI Analysis | Feedback

AI Analysis | Feedback

Warren Foust
Interim Co-Chief Executive Officer, President and Chief Operating Officer

Mr. Foust was appointed interim co-Chief Executive Officer of STAAR Surgical, effective February 1, 2026. He joined the company in April 2023 as Chief Operating Officer and was promoted to President and Chief Operating Officer in March 2025. Before joining STAAR, Mr. Foust served as Worldwide President, Surgical for Johnson & Johnson Vision from December 2019 to April 2023, where he managed a global surgical business with approximately 5,000 employees. Prior to that, he was Worldwide President of Mentor, a Johnson & Johnson business unit, from 2018-2019, and Vice President, U.S. Sales and Marketing from 2015-2018. He also held various sales leadership roles at DePuy Synthes, another Johnson & Johnson company, and began his career at Roche Pharmaceuticals in 1999.

Deborah Andrews
Interim Co-Chief Executive Officer, Chief Financial Officer

Ms. Andrews was appointed interim co-Chief Executive Officer of STAAR Surgical, effective February 1, 2026, and also serves as Chief Financial Officer, a role she officially took on effective June 25, 2025. She rejoined STAAR in March 2025 as Interim CFO and had previously served as the company's CFO from 2007-2013 and again from 2017-2020. In her capacity as CFO, she oversees STAAR's finance, accounting, internal audit, information technology, and investor relations functions. Since April 2014, Ms. Andrews has been a member of the Board of Directors of Lineage Cell Therapeutics, a clinical-stage biotechnology company, where she currently chairs the Audit Committee and previously chaired the Compensation Committee.

Magda Michna, PhD
Chief Development Officer

Dr. Michna was promoted to Chief Development Officer in March 2025, an expanded role where she oversees STAAR's clinical, regulatory, medical affairs, quality, and research and development (R&D) functions. She joined STAAR Surgical in April 2023 as Chief Clinical, Regulatory and Medical Affairs Officer. Prior to STAAR, Dr. Michna served as Chief Global Clinical, Medical and Regulatory Affairs Officer of AcuFocus, Inc. from April 2018 until its acquisition by Bausch & Lomb in January 2023. She also served as Chief Clinical Officer at Presbia, PLC. From 2012 to 2017, Dr. Michna was responsible for leading clinical development for various premium intraocular lens and other surgical device technologies within the Alcon Surgical franchise.

AI Analysis | Feedback

Key Risks to STAAR Surgical (STAA)

• Geographic Concentration and Economic Volatility in China: STAAR Surgical is highly dependent on the Chinese market, which has experienced significant economic headwinds, including inventory corrections and weakened consumer confidence. This overexposure to a single market poses a substantial risk, as downturns in China have directly impacted the company's sales and profitability.
• Intense Market Competition: The refractive surgery sector is highly competitive, with STAAR Surgical facing challenges from established vision correction methods such as LASIK and SMILE, as well as emerging domestic competitors, particularly in China. This competition can lead to price pressures, a reduction in market share, and limits on growth, especially given STAAR's primary reliance on its Implantable Collamer Lens (ICL) technology.
• Regulatory Hurdles and Product Approval: As a medical device manufacturer, STAAR Surgical is subject to extensive and evolving global government regulations. The company faces ongoing risks related to the discretion of regulatory agencies in approving or rejecting new or improved products, imposing new compliance costs, or delaying market access. Delays or failures in obtaining regulatory approvals for its ICL products can significantly hinder its ability to introduce new technologies and expand its market presence.

AI Analysis | Feedback

AI Analysis | Feedback

STAAR Surgical Company (NASDAQ: STAA) primarily focuses on its Visian implantable Collamer lens (ICL) product family, which treats visual disorders such as myopia, hyperopia, astigmatism, and presbyopia. The company has largely shifted its focus away from preloaded silicone cataract intraocular lenses to concentrate on refractive lens exchange with ICLs.

Addressable Market Sizes:

• Implantable Collamer Lens (ICL) Market (Global): The global implantable collamer lens market was valued at approximately $19.53 billion in 2024. This market is projected to grow to $20.91 billion in 2025, with an anticipated compound annual growth rate (CAGR) of 7.10%, and is expected to reach $27.25 billion by 2029.
• Myopia and Presbyopia Treatment Market (Global): The broader global market for myopia and presbyopia treatment, which ICLs address, was valued at approximately $21.8 billion in 2025 and is estimated to reach $45.4 billion by 2033, growing at a CAGR of 9.7%. Another estimate places this market at $27.47 billion in 2025, expected to reach $35.24 billion by 2030, with a CAGR of 5.11%.
• U.S. Addressable Market for EVO/EVO+ Visian ICL: The U.S. age indication for EVO/EVO+ Visian ICL was expanded to 21–60 years, increasing the addressable market by nearly 8 million U.S. adults. Approximately 100 million people in the United States aged 21 to 45 who suffer from myopia may be candidates for EVO ICL. The immediate target market for surgical procedures is estimated at 5.2 million procedures in 2025, with a broader potential market including 2.7 billion people globally with myopia.

AI Analysis | Feedback

1. Expanded Age Indication for EVO ICL in the U.S.: The U.S. Food and Drug Administration (FDA) has approved an expanded age indication for STAAR Surgical's EVO/EVO+ Visian Implantable Collamer Lenses (ICL), extending eligibility for patients from 21-45 years to 21-60 years old. This expansion could add nearly 8 million potential refractive patients to the market. This approval, supported by strong long-term safety data, is expected to drive higher procedure volumes and bolster surgeon confidence.
2. Recovery and Growth in the China Market: China, STAAR Surgical's largest market, experienced a period of macroeconomic volatility and inventory adjustments in 2025. However, in-market EVO ICL demand showed recovery at mid-single-digit rates, and market conditions are anticipated to rebound in 2026, which is expected to significantly contribute to STAAR's growth.
3. Launch and Scaling of New Products, including EVO+ in China: STAAR Surgical has launched EVO+ in China, marking its first new lens in the region in over a decade, with early demand proving encouraging. The company's development pipeline is also expected to offer additional advancements in lens-based refractive surgery, further expanding its addressable market.
4. Global Market Penetration and International Expansion: STAAR Surgical is strategically focused on increasing patient awareness and adoption of ICL procedures as an alternative to LASIK and on strengthening partnerships with eye care professionals globally. Efforts are underway to expand into new markets, with regulatory approvals in Taiwan in 2025 and planned expansion in markets like Taiwan and Canada in 2026 and beyond. The global phakic intraocular lenses (IOLs) segment is projected to continue its significant market share expansion.
5. Accelerated Shift Towards Lens-Based Vision Correction: There is an ongoing trend in refractive surgery where patients are increasingly opting for lens-based procedures, such as ICLs, over laser vision correction methods that involve corneal tissue removal. STAAR's EVO ICL continues to gain market share despite the broader struggles in the laser vision correction market, positioning the company for continued growth.

AI Analysis | Feedback

Share Repurchases

• In May 2025, STAAR Surgical's Board of Directors authorized a share repurchase program of up to $30 million of its common stock.
• For the fiscal year ended January 2, 2026, the company repurchased approximately 376,000 shares for a total cost of approximately $6.5 million under the May 2025 program.
• As of January 2, 2026, approximately $23.5 million remained available under the existing share repurchase authorization.

Share Issuance

• Information regarding the dollar amount of shares issued by STAAR Surgical over the last 3-5 years is not available in the provided search results.

Inbound Investments

• Alcon proposed to acquire STAAR Surgical in a merger agreement, which would have seen STAAR stockholders receive $30.75 per share in cash, representing an approximate $1.6 billion valuation for the transaction. However, this merger agreement was terminated in January 2026 after STAAR shareholders failed to approve the transaction.
• Broadwood Partners purchased approximately $41 million worth of STAAR Surgical shares between November 19 and November 21, 2025, increasing their direct ownership in the company to over 15 million shares.

Outbound Investments

• STAAR Surgical has made no reported outbound investments or acquisitions of other companies within the last 3-5 years.

Capital Expenditures

• STAAR Surgical's historical capital expenditures were $15 million in 2024 and $13 million in 2023.
• Projected capital expenditures are $13 million for 2025, $14 million for 2026, and $15 million for 2027.
• The primary focus of capital expenditures includes research and development for new presbyopia-correcting phakic intraocular lenses, preloaded injector systems, next-generation ophthalmic medical devices and materials, and manufacturing optimization, including accelerating manufacturing expansion in Switzerland to mitigate tariff exposure and support the launch of EVO+ in China.